Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zynex ( (ZYXI) ) has issued an announcement.
On August 18, 2025, Zynex, Inc. announced the appointment of Vikram Bajaj as Chief Financial Officer and John Bibb as Chief Legal Officer, as part of a strategic move to strengthen its leadership team. These appointments, along with the addition of Steven Dyson as CEO, are aimed at enhancing the company’s operational performance and positioning it for future growth in the medical technology sector.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
Spark’s Take on ZYXI Stock
According to Spark, TipRanks’ AI Analyst, ZYXI is a Neutral.
Zynex’s overall stock score is primarily impacted by its financial struggles, including declining revenue and profitability, and technical indicators showing bearish trends. While strategic initiatives and leadership changes offer some hope, the current challenges outweigh these positives.
To see Spark’s full report on ZYXI stock, click here.
More about Zynex
Zynex, Inc., established in 1996, is a medical technology company that develops, manufactures, and sells non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The company focuses on providing innovative solutions for hospitals and healthcare providers.
Average Trading Volume: 324,609
Technical Sentiment Signal: Sell
Current Market Cap: $46.05M
See more data about ZYXI stock on TipRanks’ Stock Analysis page.